An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression
CA Zarate Jr, JA Quiroz, JB Singh, KD Denicoff… - Biological …, 2005 - Elsevier
BACKGROUND: Preclinical and clinical evidence indicate that the glutamatergic system
might play a role in the pathophysiology of mood disorders. This study was conducted to
determine the efficacy and safety of riluzole, a glutamate-modulating agent, in bipolar
depression. METHODS: This was an 8-week add-on study of riluzole in combination with
lithium in acutely depressed bipolar patients aged 18 years and older. After open treatment
with lithium for a minimum period of 4 weeks, subjects who continued to have a Montgomery …
might play a role in the pathophysiology of mood disorders. This study was conducted to
determine the efficacy and safety of riluzole, a glutamate-modulating agent, in bipolar
depression. METHODS: This was an 8-week add-on study of riluzole in combination with
lithium in acutely depressed bipolar patients aged 18 years and older. After open treatment
with lithium for a minimum period of 4 weeks, subjects who continued to have a Montgomery …
以上显示的是最相近的搜索结果。 查看全部搜索结果